Benchmark raised the firm's price target on RCM Technologies to $36 from $32 and keeps a Buy rating on the shares following a Q4 beat driven by stronger operating leverage on inline revenue. The firm retains a cautious view on a rebound in Life Sciences in FY26, but sees potential upside in Engineering Services, the analyst tells investors in a post-earnings note.
